Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra plus allopurinol escalation versus standard care in acute gout with coronary CT assessment
ACTRN12620001185954Phase 3Not yet recruiting
- Sponsor
- Fiona Stanley Hospital
- Start
- Dec 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anakinra in gout (2 arms), sponsored by Fiona Stanley Hospital. Primary endpoints: High-risk rupture-prone coronary plaque burden and Non-calcified coronary plaque burden. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
anakinra
03
Conditions
gout
Beyond the preview
Go deeper on ACTRN12620001185954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001185954.